Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19289729 | 1.00 | LMNA (0.49) | LMNAGAAMAPTESR2ESR1 | |
| SCHEMBL94115 | 0.86 | ESR2 (0.49) | LMNAGAAMAPTESR2DRD2 | |
| SCHEMBL20708198 | 0.81 | ESR2 (0.45) | LMNAGAAMAPTESR2ESR1 | |
| SCHEMBL6581441 | 0.81 | ESR1 (0.61) | LMNAESR2ESR1DRD2DRD4 | |
| SCHEMBL3526361 | 0.81 | LMNA (0.46) | LMNAGAAMAPTDRD4BRD4 | |
| SCHEMBL1734493 | 0.81 | LMNA (0.46) | LMNAGAAMAPTDRD4BRD4 | |
| SCHEMBL1735337 | 0.81 | LMNA (0.46) | LMNAGAAMAPTDRD4BRD4 | |
| SCHEMBL12965849 | 0.79 | AR (0.45) | LMNAGAAMAPTBRD4CREBBP | |
| SCHEMBL7922397 | 0.78 | GAA (0.47) | LMNAGAAMAPTBRD4CREBBP | |
| SCHEMBL30101714 | 0.78 | GAA (0.47) | LMNAGAAMAPTBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | LMNA 2126/4885GAA 3495/4885MAPT 3910/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | LMNA 2126/4885GAA 3495/4885MAPT 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.